Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XTL Biopharmaceuticals has signed a strategic collaboration framework agreement with Clalit Research Institute, the research unit of Clalit Health Services, and Mor Research Applications, the technology transfer office of Clalit Health Services.
Subscribe to our email newsletter
The research institute will supply XTL with clinical data and analyses as part of the agreement.
The data and analyses would be based on the Institute’s database in connection with technologies that come from innovations and patents of Clalit Health Services’ physicians.
The data will help XTL to assess safety and efficacy data, which will be used to design and evaluate the company’s clinical trials and new projects.
XTL chief executive officer David Grossman said the collaboration with the research institute directly supports the company’s clinical development pipeline.
"This strategic collaboration represents another important link in the ecosystem we are building around our cutting-edge technologies focused on clinical development," Grossman said.
XTL has already licensed two technologies from Mor, which include SAM-101 for the treatment of psychotic patients and rHuEPO for the treatment of multiple myeloma blood cancer.